AcquisitionsJul 22, 2026, 06:03 AM
Repligen to Acquire BioLife Solutions for $1.5B
AI Summary
Repligen Corporation announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion in total enterprise value. The transaction, comprising 64% Repligen common stock and 36% cash, is expected to be accretive to Repligen's top-line growth, adjusted margins, and adjusted EPS by at least $0.05 in year one and $0.25 in year two. The acquisition aims to strengthen Repligen's position in the high-growth cell therapy market. Both companies also reported preliminary Q2 2026 revenue growth, with Repligen at 12% reported (13% organic) and BioLife at 21% year-over-year to $28.5 million.
Key Highlights
- Repligen to acquire BioLife Solutions for approximately $1.5 billion total enterprise value.
- BioLife stockholders to receive $31.00 per share ($11.25 cash, 0.1442 Repligen common shares).
- Transaction expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one.
- Expected to be accretive to Repligen's adjusted EPS by at least $0.25 in year two.
- Anticipates at least $20 million in synergies in year one and $30 million in year two.
- Repligen reports preliminary Q2 revenue growth of approximately 12% (13% organic).
- BioLife reports preliminary Q2 revenue of $28.5 million, up 21% year-over-year.
- The acquisition is expected to close in the fourth quarter of 2026.
Price Impact
More from RGEN